Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: A randomized comparison Conference Paper


Authors: Bosl, G. J.; Bajorin, D. F.
Title: Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: A randomized comparison
Conference Title: Fox Chase Cancer Center Workshop on the Role of Platinum Compounds in Cancer Treatment
Abstract: Two hundred sixty-five evaluable patients were randomized to receive either carboplatin/etoposide (131 patients) or cisplatin/etoposide (134 patients). Among the carboplatin-treated patients, 115 (88%) achieved a complete remission, compared with 121 (90%) of patients receiving cisplatin. In the carboplatin group, however, 16 patients (12%) relapsed following complete remission, in contrast to four (3%) of those receiving cisplatin. Thus, the total number of unfavorable events (incomplete response + relapse) was 32 (24%) in the carboplatin arm, compared with 17 (13%) in the cisplatin arm (P = .02). In addition, patients receiving carboplatin had a greater likelihood of being hospitalized for neutropenia and fever (P = .016) and had lower platelet nadirs (P < .001). It was concluded that carboplatin administered at the dose and schedule used in this clinical trial resulted in an inferior event-free survival rate and worse toxicity than cisplatin, and is not recommended for use in general practice.
Keywords: adolescent; adult; controlled study; aged; middle aged; survival rate; major clinical study; clinical trial; neutropenia; cancer recurrence; cisplatin; dose response; conference paper; carboplatin; controlled clinical trial; anemia; etoposide; randomized controlled trial; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; drug administration schedule; fever; cancer regression; testicular neoplasms; thrombocyte count; remission induction; germ cell tumor; seminoma; intravenous drug administration; ototoxicity; germinoma; humans; human; male; priority journal
Journal Title Seminars in Oncology
Volume: 21
Issue: 5 Suppl. 12
Conference Dates: 1993 Feb 24-28
Conference Location: Kona, HI
ISBN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 1994-10-01
Start Page: 61
End Page: 64
Language: English
PUBMED: 7992068
PROVIDER: scopus
DOI/URL:
Notes: Conference Paper -- Export Date: 14 January 2019 -- Source: Scopus
Citation Impact
MSK Authors
  1. Dean Bajorin
    657 Bajorin
  2. George Bosl
    430 Bosl